← All stocks

Zentalis Pharmaceuticals, Inc.

ZNTL No buying or selling
CIK 0001725160 #3371 in the set updated 17 Sep 2026
Bought (1 mo)
$0.00
out of their own pocket, the only kind of buying there is
Sold (1 mo)
$0.00
$0.00 on a plan · $0.00 straight out of an exercise
Sold at will
$0.00
0 of 0 sales
Net
$0.00
$0.00 against sales at will

By person

13 insiders · 0 transactions
0.3×

Julie Eastland holds only 0.3 times base salary in stock. $276.97K of shares against $700.00K in salary for 2025.

Salary from the company's own proxy. The shares are what Julie Eastland last reported holding, valued at $3.50, the price Common Stock was last bought or sold at on the open market here, on 14 Aug 2026.

Insider
Role
Bought
Sold
Net
Holding
Worth
Change
WALTERS GROUP entity
10% owner
17,844,973
$62.46M
+153.1%
Matrix Capital Management Company, LP entity
10% owner
6,459,973
$22.61M
−53.7%
Paul Andrea
Chief Legal Officer
1,070,784
$3.75M
+614.0%
Lackner Mark
Chief Scientific Officer
512,856
$1.79M
+162.0%
Myers Scott Dunseth
Director
395,895
$1.39M
Johnson David Michael
Director
307,521
$1.08M
+59.5%
Skvarka Jan
Director
264,254
$924.89K
+195.1%
Walker Luke Nathaniel
Director
201,384
$704.84K
+177.8%
Kariuki Enoch
Director
194,465
$680.63K
+143.8%
Vultaggio Vincent
PAO and PFO
146,506
$512.77K
+313.2%
Campbell Shannon
Director
114,200
$399.70K
EASTLAND JULIA MARIE
CEO & President
79,133
$276.97K
Bruns Ingmar
Chief Medical Officer
33,332
$116.66K

No percentages here. These insiders hold more than one class of share between them, and the share count on file covers one of them rather than all. Dividing the two would compare different things.

Nothing of that kind in this period.

What was left out

Form 4 filings counted 1
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 1
Sales on a Rule 10b5-1 plan 0
Sales straight out of an exercise 0
Sales at will 0
Transactions with no price 0
Shares from compensation/vesting 0
History held since 8 Apr 2020